PKCθ inhibitor 14   Click here for help

GtoPdb Ligand ID: 9452

Synonyms: compound 14 [PMID: 27117263]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: PKCθ inhibitor 14 was developed using structure-based drug design [1]. The compound is described as being selective for PKCθ, over other kinases, including related PKC isoforms.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 82.5
Molecular weight 413.19
XLogP 4.42
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C1NC(C)(C)N(c2c1ccc(c2)n1c(=O)[nH]c2c1cccn2)C(c1ccccc1)C
Isomeric SMILES O=C1NC(C)(C)N(c2c1ccc(c2)n1c(=O)[nH]c2c1cccn2)[C@@H](c1ccccc1)C
InChI InChI=1S/C24H23N5O2/c1-15(16-8-5-4-6-9-16)29-20-14-17(11-12-18(20)22(30)27-24(29,2)3)28-19-10-7-13-25-21(19)26-23(28)31/h4-15H,1-3H3,(H,27,30)(H,25,26,31)/t15-/m1/s1
Immunopharmacology Comments
PKCθ inhibitor 14 inhibits IL-2 production in the T-cell signaling pathway, demonstrating potential efficacy for treatment of inflammatory diseases associated with T-cell responses [1].